spacer
The Healthcare Sales & Marketing Network celebrates 21 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Indivior 

 HSMN NewsFeed - 22 Feb 2019
Mylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
Biopharmaceuticals Drug Delivery Generics Product Launch
 HSMN NewsFeed - 19 Dec 2018
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 23 Nov 2018
Indivior Announces Health Canada Approval of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 May 2018
Indivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 14 May 2018
Aquestive Therapeutics Settles Patent Infringement Case with Par Pharmaceuticals
Biopharmaceuticals Drug Delivery Generics Litigation
 HSMN NewsFeed - 9 May 2018
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery Surgery Licensing
 HSMN NewsFeed - 23 Apr 2018
OrphoMed Appoints Gary M. Phillips, M.D. as President and Chief Executive Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 1 Mar 2018
SUBLOCADE(TM) (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the U.S. to Treat Patients with Moderate to Severe Opioid Use Disorder
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 7 Oct 2016
Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 6 Oct 2016
U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)
Biopharmaceuticals FDA
Return to NewsFeed  
FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.